BEPPELS WL 23.06.:
- $FIRY, 8.5 $, 10.65 mln float, ticker change from $sklz yesterday, last ticker change $FTH went from 14 to 23 in just 3 days with 25 mln float, 0 dilution, 132 mln mc, 233 mln cash! ✅
- $SUGP, 1 $, 3.5 mln float, 1.75 $ cash per share, had multiple spikes from here to 1.3-2.8 in just one week! ✅
- $GITS, 1.8 $, 3.3 mln float, halted up in overnite, no news to find, with 872 % ctb shorts could be in big trouble today! ✅
- $LRHC, 1.1 $, 1.6 mln float, diversifying into AI data centers, market hasn t priced this shift in! ✅
- $BRAI, 7.5 $, 1.7 mln float, perfect loading zone, 780 % ctb, just last week they did a 100 k promo and hit 11.5! Low risk swing from here! ✅
Also watch $mwc, $dss,
$rdgt, $pfsa!
👀 🔥 👀
SpaceX just acquired Cursor for $60B
> be Cursor
> 4 MIT students start a side project in 2022
> build the AI coding tool developers love
> hit a $10B valuation
> decide copilots aren’t enough
> move into models
> need massive compute to compete with OpenAI, Anthropic & Google
> meanwhile xAI is losing the coding race
> realizes catching up could take years
> skips the line
> buys Cursor for $60B
> Cursor gets compute
> xAI gets the coding leader
> founders become multi-billionaires
$OTLK
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD. The Company has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.